Permatage XT Settable Nonabsorbable Hemostatic Bone Putty (OS-PER-1001XT)
K262769 · Orthocon, Inc. · MTJ · Sep 3, 2026 · OR
Device Facts
| Record ID | K262769 |
| Device Name | Permatage XT Settable Nonabsorbable Hemostatic Bone Putty (OS-PER-1001XT) |
| Applicant | Orthocon, Inc. |
| Product Code | MTJ · OR |
| Decision Date | Sep 3, 2026 |
| Decision | SESE |
| Submission Type | Special |
| Device Class | Class U |
| Attributes | Therapeutic |
Indications for Use
Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is indicated for the control of bleeding from cut or damaged bone by acting as a mechanical barrier or tamponade.
Device Story
Two-part, sterile, nonabsorbable bone putty; components (granular calcium phosphate, paraffin oil, vitamin E acetate, triglyceride, polyether-based polymers) mixed immediately prior to use; forms cohesive, putty-like material; manually applied by clinician to bone surface; acts as mechanical barrier/tamponade to control bleeding; sets within minutes; non-exothermic; remains in place as permanent implant; radiopaque.
Clinical Evidence
No clinical studies conducted. Evidence includes biocompatibility testing (ISO 10993-1: cytotoxicity, irritation, sensitization, systemic toxicity, genotoxicity, local tissue toxicity, hemolysis, pyrogenicity, neurotoxicity), benchtop performance testing (working time comparison), and in-vivo animal testing for hemostatic efficacy.
Technological Characteristics
Two-part putty; materials: granular calcium phosphate, paraffin oil, vitamin E acetate, triglyceride, polyether-based polymers; radiopaque (hydroxyapatite/beta-tricalcium phosphate); nonabsorbable; sterile (gamma irradiation); manual application; 4-minute working time; no exothermic reaction.
Indications for Use
Indicated for control of bleeding from cut or damaged bone via mechanical barrier or tamponade.
Predicate Devices
- HBP7 Settable Hemostatic Bone Putty (K202363)
Reference Devices
- Permatage XT Settable Bone Putty (K261265)
Submission Summary (Full Text)
{1}
**FDA** U.S. FOOD & DRUG
ADMINISTRATION
September 3, 2026
Orthocon, Inc.
Alyssa McDermott
Sr. Director, Quality and Regulatory Affairs
700 Fairfield Ave., Suite 1
Stamford, Connecticut 06902
Re: K262769
Trade/Device Name: Permatage XT Settable Nonabsorbable Hemostatic Bone Putty
Regulatory Class: Unclassified
Product Code: MTJ
Dated: August 4, 2026
Received: August 4, 2026
Dear Alyssa McDermott:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{2}
K262769 - Alyssa McDermott
Page 2
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
{3}
K262769 - Alyssa McDermott
Page 3
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Robert M. Stefani -S
Digitally signed by Robert M.
Stefani -S
Date: 2026.09.03 09:44:13 -04'00'
For: Jesse Muir, Ph.D.
Assistant Director
DHT6C: Division of Restorative,
Repair, and Trauma Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{4}
| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K262769 | ? |
| Please provide the device trade name(s). | | ? |
| Permatage XT Settable Nonabsorbable Hemostatic Bone Putty | | |
| Please provide your Indications for Use below. | | ? |
| Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is indicated for the control of bleeding from cut or damaged bone by acting as a mechanical barrier or tamponade. | | |
| Please select the types of uses. | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? |
| Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☐ Adolescents (12 years old to < 22 years old) ☐ Adults (22 years old and greater) | ? |
{5}
K262769
# Permatage XT Settable Nonabsorbable Hemostatic Bone Putty
Special 510(k) SUMMARY (Per 21 CFR 807.92)
# General Company Information:
| Name: | Orthocon, Inc. |
| --- | --- |
| Contact: | Alyssa McDermott Senior Director of Quality and Regulatory Affairs |
| Address: | 700 Fairfield Avenue, Suite 1 Stamford, CT 06902 |
| Telephone: | (855) 475 - 9175 |
# Date Prepared:
August 24th, 2026
# General Device Information:
| Product Name: | Permatage XT Settable Nonabsorbable Hemostatic Bone Putty |
| --- | --- |
| Common Name: | Bone Wax |
| Classification: | Class II |
| Product codes: | MTJ |
# Predicate Device:
| Orthocon, Inc. | HBP7 Settable Hemostatic Bone Putty [510(k) Number K202363] |
| --- | --- |
| | Reference Device: Permatage XT Settable Bone Putty [510(k) Number K261265] |
# Device Description
Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is a sterile, biocompatible, nonabsorbable material of putty-like consistency for the control of bleeding from cut or damaged bone. The single use Permatage XT Settable Nonabsorbable Hemostatic Bone Putty device contains two separate components of putty-like consistency comprised of granular calcium phosphate, paraffin oil, vitamin E acetate, a triglyceride, and a mixture of nonabsorbable, polyether-based polymers. When mixed together, the components of the Permatage XT Settable Nonabsorbable Hemostatic Bone Putty device form a nonabsorbable cohesive, putty-like material that adheres to the bone surface and remains in place following application. The resulting hardening material is primarily calcium phosphate and nonabsorbable polymer materials. Permatage XT Settable Nonabsorbable Hemostatic Bone Putty components must be mixed immediately prior to use.
# Indications for Use
Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is indicated for the control of bleeding from cut or damaged bone by acting as a mechanical barrier or tamponade.
The following table shows comparisons of characteristics of Permatage XT Settable Nonabsorbable Hemostatic Bone Putty and the predicate device.
1
{6}
K262769
Permatage XT Settable Nonabsorbable Hemostatic Bone Putty - Special 510(k)
| | HBP7 Settable Hemostatic Bone Putty (K202363, Primary Predicate) | Permatage XT Settable Nonabsorbable Hemostatic Bone Putty (K262769) |
| --- | --- | --- |
| Indications | HBP7 Settable Hemostatic Bone Putty is indicated for the control of bleeding from cut or damaged bone by acting as a mechanical barrier or tamponade. | Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is indicated for the control of bleeding from cut or damaged bone by acting as a mechanical barrier or tamponade. |
| Product Code | Product Code MTJ | Product Code MTJ |
| Product Consistency | HBP7 Settable Hemostatic Bone Putty is formulated as a two-part putty/putty device that forms a "settable" (hardening) material when mixed at the time of surgery. At the time of application, device is in the form of a spreadable material. | Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is formulated as a two-part putty/putty device that forms a "settable" (hardening) material when mixed at the time of surgery. At the time of application, device is in the form of a spreadable material. |
| Application | Device is designed to be manually applied to the bone surface. | Device is designed to be manually applied to the bone surface. |
| Components | HBP7 Settable Hemostatic Bone Putty is indicated for the control of bleeding from cut or damaged bone by acting as a mechanical barrier or tamponade. The single use HBP7 Settable Hemostatic Bone Putty device contains two separate components of putty-like consistency comprised of granular calcium phosphate, paraffin oil, vitamin E acetate, a triglyceride, and a mixture of nonabsorbable, polyether-based polymers. When mixed together, the components of the HBP7 Settable Hemostatic Bone Putty device form a nonabsorbable cohesive putty-like material that adheres to the bone surface and remains in place following application. The resulting hardening material is primarily comprised of calcium phosphate and nonabsorbable polymer materials. | Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is indicated for the control of bleeding from cut or damaged bone by acting as a mechanical barrier or tamponade The single use Permatage XT Settable Nonabsorbable Hemostatic Bone Putty device contains two separate components of putty-like consistency comprised of granular calcium phosphate, paraffin oil, vitamin E acetate, a triglyceride, and a mixture of nonabsorbable, polyether-based polymers. When mixed together, the components of the Permatage XT Settable Nonabsorbable Hemostatic Bone Putty device form a nonabsorbable cohesive putty-like material that adheres to the bone surface and remains in place following application. The resulting hardening material is primarily comprised of calcium phosphate and nonabsorbable polymer materials. |
| Radiopacity | Radiopaque - Contains hydroxyapatite and β-tricalcium phosphate. | Radiopaque - Contains hydroxyapatite and β-tricalcium phosphate. |
| Implant Life | Implanted device is nonabsorbable. | Implanted device is nonabsorbable. |
| Sterilization | Single-patient-use device is provided sterile by gamma irradiation. | Single-patient-use device is provided sterile by gamma irradiation. |
| Unit Sizes | The bone putty is available in individual sizes of up to 10cc. | The bone putty is available in individual sizes of up to 10cc. |
| Packaging | The putty is provided in two foil packages each within a Tyvek/LDPE pouch, within a single outer foil pouch. The outer foil pouch contains a desiccant. The pouch is heat sealed and terminally sterilized via gamma irradiation. | The putty is provided in two foil packages each within a Tyvek/LDPE pouch, within a single outer foil pouch. The outer foil pouch contains a desiccant. The pouch is heat sealed and terminally sterilized via gamma irradiation. |
| Mixing | Mixing for homogeneity takes 45 seconds. | Mixing for homogeneity takes 45 seconds. |
| Setting | Material sets within minutes following application. | Material sets within minutes following application. |
| Working Time | Material provides a working time of 2 minutes. | Material provides a working time of 4 minutes. |
| Exotherm | Device cures with no appreciable exothermic reaction. | Device cures with no appreciable exothermic reaction. |
2
{7}
K262769
## Biocompatibility Testing
Biocompatibility testing was leveraged from the reference device, Permatage XT Settable Bone Putty, to evaluate biocompatibility in accordance with the recommendations of ISO 10993-1. The following biocompatibility studies were conducted on the final, finished, gamma-irradiation sterilized device and in accordance with the GLP requirements: cytotoxicity, irritation, sensitization, systemic toxicity, genotoxicity, local tissue toxicity, hemolysis, pyrogenicity and neurotoxicity.
## Benchtop Performance Testing
Because the only clinically meaningful difference between the predicate device and subject device is the working time, only one benchtop study was conducted to compare the working time of the predicate device to Permatage XT Settable Nonabsorbable Hemostatic Bone Putty. Results confirm the extended working time presented in the labeling.
All other studies submitted for the primary predicate device in K202363 are unchanged and are directly applicable to the subject device, Permatage XT Settable Nonabsorbable Hemostatic Bone Putty. The studies conducted using the predicate include temperature sensitivity, dissolution and swelling, *in vitro* degradation, and electrocautery compatibility.
## In-Vivo Testing
In-vivo animal testing was used to evaluate Permatage XT Settable Nonabsorbable Hemostatic Bone Putty and the predicate for hemostatic efficacy. The study successfully met all acceptance criteria, confirming that Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is an effective mechanical hemostatic tamponade equivalent to the predicate.
## Clinical Testing
No clinical studies have been conducted in support of this Special 510(k).
## Conclusions
This submission supports the position that Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is substantially equivalent to the predicate device.
The information provided establishes that Permatage XT Settable Nonabsorbable Hemostatic Bone Putty is substantially equivalent to the legally marketed predicate HBP7 Settable Hemostatic Bone Putty, when used for the same clinical application as a bone hemostat. Any differences between Permatage XT Settable Nonabsorbable Hemostatic Bone Putty and the predicate do not raise new concerns or risks.
3